The G20

Health & Development Partnership


Keep up to date with events as they unfold.


We are delighted that Prof. @RifatAtun joined our @G20Partnership as a Global Ambassador. We look forward to collaborating with him to promote healthy nations by looking at innovative finance mechanisms to achieve sustainable economies beyond 2030

.@WHO We are extremely sad to hear of the death of Peter Salama, WHO. The G20 HDP passes on our heartfelt condolences to Peter's family, friends and colleagues. Peter was a first class public servant who embodied the WHO commitment to Universal Health Coverage.

Speaking at @wef @AlanDonnelly57 called for greater use of innovative & blended finance initiatives to fund Health innovation, R&D in tackling infectious, non communicable diseases and the Common Goods for Health #Davos2020 @AJack @andreafeigl1 @FT @HealthFinInst @haraldnusser

Speaking at the #WEF20 @AlanDonnelly57 calls for the IMF Article 4 Consultation Mandate to be reviewed so that strategic national investments in public health planning are encouraged #IMF

Load More...


The Real Consequences of Fake Medicines

David Richmond, Chief Executive, Brazzaville Foundation

This month, African leaders will pledge to introduce tough criminal legislation to combat the proliferation of substandard and fake medical products – a deadly business that disproportionately affects the poorest and most vulnerable. They need and deserve international support.

Niger’s government is sounding the alarm about bogus meningitis vaccines – and it is not the first time. Five years ago, hundreds of Nigerien people died after receiving fake vaccines. The problem, of course, is not vaccines. It is the widespread distribution of substandard and falsified medical products. And it is a problem that disproportionately affects Africa.

The global market for medicines that are substandard (failing to meet quality specifications) or falsified (with the composition, identity, or source deliberately misrepresented) is estimated to be worth up to $200 billion, or 10-15% of the total pharmaceutical market. But it could be much bigger: according to the World Health Organization, which relies largely on voluntary reporting by health-care professionals, we may know about “just a small fraction” of all cases. What we do know is that the problem is particularly acute in Africa. In 2013-2017, 42% of substandard and falsified medicines found were on the continent. This is undermining Africa’s hard-won progress on health, not least by eroding trust in nascent health-care systems. Needless to say, the use of substandard or falsified medicines – which range from ineffective to poisonous – can have devastating consequences, with the poorest and most vulnerable being hit the hardest. After all, it is those with limited funds and poor access to medical professionals and quality health care who are most likely to buy discounted medicines on the streets, where there is no guarantee that they are real, let alone of high quality. Ultimately, this can result in much higher costs for victims, who must pay more to treat the original illness once it has progressed further, as well as for any side effects from the fake medication, if they survive at all. A 2015 study estimated that, in Sub-Saharan Africa, 122,000 children under the age of five had died in just one year as a result of substandard or falsified antimalarial medications. Moreover, since people don’t know what they are taking, let alone the proper dose, falsified and substandard medicines contribute to rising antimicrobial resistance – a trend that doesn’t discriminate between rich and poor. Yet fake-medicine traffickers have little incentive to stop. It is estimated that every $1,000 traffickers “invest” in counterfeit medicines can yield as much as $450,000 in profit. That margin is 10-25 times larger than that enjoyed by sellers of illicit narcotics. And those massive rewards are not counterbalanced by significant risk. Even when caught, fake-medicine traffickers often avoid prison time. They merely pay a fine and get back to business.

David Richmond is Chief Executive of the Brazzaville Foundation, an independent London-based charity that focuses on African issues. This op-ed originally appeared on on 15 January 2020.

A note on the G20 Health and Development Partnership: the threat posed by substandard and falsified medicines is expanding beyond Africa and is also a concern for G20 nations. Under this year’s G20 Presidency, led by the Kingdom of Saudi Arabia, it is of utmost importance that G20 leaders focus on combatting the scale of this challenge, as it not only promotes the financing of terrorism, but is also a huge burden on national economies. Moreover, there is an opportunity under this year’s G20 health agenda and its focus on patient safety, to address the dangers posed by substandard and falsified medicines on patients.


The Cost of Patient Safety Inaction: Why doing more of the same is unsustainable?!

by Abdulelah M. Alhawsawi – Saudi Patient Center

On January 2020, Patient Safety will be on the G20 agenda (amongst other five health key priorities). One would ask: What is Patient Safety doing on an economic forum like the G20? Another cynic might even add: What is Healthcare doing on the G20?

The G20 was established in the late 1990s with the objective of its members working together to achieve economic and financial stability. It is comprised of 19 countries and the European Union (EU). The G20 collectively represent more than 85 % of the world’s Gross Domestic Product (GDP), and more than two- thirds of the world’s population.

Healthcare was only introduced in 2017 during the German presidency.


Patient harm is estimated to be the 14th leading cause of the global disease burden. This is comparable to medical conditions such as tuberculosis and malaria. In both U.S. and Canada, Patient Safety Adverse Events represent the 3rd leading cause of death, preceded only by cancer and heart disease. In the U.S. alone: 440 thousand patients die annually from healthcare associated infections (HAIS). In Canada: there are more than 28 thousand deaths a year due to Patient Safety Adverse Events. In Low – Middle Income Countries (LMIC), every year 134 million adverse events take place resulting in 2.6 million deaths annually. Having said all that, up to 70 % of harm is . (OECD, 2017)

In addition to lives lost and harm inflicted, unsafe medical practice results in money loss.  Nearly, 15 % of the health expenditure across Organization of Economic Cooperative Development (OECD) countries is attributed to patient safety failures each year (OECD 2017)  But if we add the indirect and opportunity cost  Economic & Social), the cost of harm could amount to trillions of dollars globally (OECD 2017).

According to a report by Frost & Sullivan in 2018, Patient Safety Adverse Events cost the US alone 146.1 billion dollars annually.

When you compare the cost of prevention to the cost of harm, the return on investment (ROI) becomes a “no brainer”.  In a study that looked at patient safety ROI for Pressure Injuries, the cost of prevention was € 291.33 million compared to the cost of harm of € 2.59 billion (almost 1,000 times higher). (Demmarre et al 2015)

Over the past 20 years, numerous efforts were made to improve patient safety in individual G20 countries as well as globally under the World Health Organization leadership. Despite all those efforts, the level of harm to patients persists and 20-40% of health resources are being wasted (WHO). Many healthcare structural causes are responsible for the ongoing harm:

  • Healthcare Workforce Factors: In addition to the quality and quantity, the wellbeing and safety of health workforce are foundational to patient safety. A substantial body of research now points to link nurse staffing with patient outcomes. A business case by Needleman (2006) demonstrated cost saving from reduced complications and shorter length of stay associated with higher nurse staffing levels. This relationship is articulated clearly in the Jeddah Declaration on Patient Safety in 2019. Dall (2009) estimated the impact of increased nurse staffing on medical cost, lives saved and national productivity. Their research suggests that adding 133,000 nurses to U.S. hospitals would save 5900 lives per year, increase productivity by $1.3 billion, or about $9900 per year per additional nurse. Decrease in length of stay resulting from this additional nurse staffing would translate into medical savings of $6.1 billion and increased in productivity attributed to decreased length of stay was estimated at $231 million per year. Addressing and ensuring guidelines that are consistent with research findings for nursing staffing in acute settings is a viable key solution to prevent medical errors, improve patient safety and decrease cost of healthcare delivery.


  • Healthcare Education Causes: Even though healthcare is provided by multi-disciplinary teams, healthcare education (undergraduate – postgraduate) continues to be conducted in separate settings. This siloed approach results in many of the communication failures / safety failures that are experienced on a regular basis. According to Joint Commission communication failures were the leading root cause of the sentinel events reported to the Joint Commission from 1995 to 2004. Healthcare education requires a serious reevaluation of its current curricula and practices. Furthermore, the lack of patient safety components to the medical and allied health sciences curriculum does a disservice to have safe medical practices imbedded within the day-to-day implementation of the healthcare workforce.
  • Patient – Provider Information Asymmetry: The information and communication gap between the healthcare providers and their patients has caused ongoing harm. With the information abundance, patients turned to the internet as a source of guidance, regardless of its accuracy, which is minimally provided by Healthcare teams. Healthcare providers need to be the trusted guidance for information and the empowering force for patients to make informed decisions. Unempowered patients may result in lack of transparence and noncompliance to the care plans that contribute patient harm. Major movement for patient empowerment and community engagement is warranted. In addition, engaging patients can reduce the burden of harm by about  15%, saving billions of dollars each year. (WHO)
  • Poor Safety Culture: The Hospital Survey on patient safety culture has been implemented in many countries to gain insight on the employees’ perception of the hospital patient safety culture. It has been consistently found that employees perceive hospital cultures lack transparency and results in punitive consequences when adverse events are reported. ‘Shame and Blame’ culture is one of the major barriers to improving safety. It is imperative that healthcare systems adopt strategies enabling Just Culture.
  • Lack of consideration of Human Factors: In the healthcare sector, and since the Institute of Medicine (IOM) report “To Err is Human”, have come a long way in improving our services with elimination of potential harm in mind. However, healthcare can learn much more from other industries that have improved safety through use of HFE in redesigning work process and flow to ensure they are error-proof. HFE is an important discipline that can embed resilience to healthcare systems and could, potentially, transform patient safety.


  • Lack of sufficient sharing and learning: The different sectors within the healthcare industry have created silos based on profession, departments, type of organization and many more subcultures and entities within a facility and at the national levels. This results in fragmented systems working in isolation, creating piece meal solutions and multi-levels of communication gaps, let alone the opportunity to share and learn in a manner that prevents harm from being repeated. Learning (from within healthcare), through Reporting & Learning Systems, and (from other industries), e.g. aviation, nuclear, oil & gas, is essential to healthcare safety innovation and transformation. Furthermore, population ageing has significant implications for patient safety as older adults are at higher risk for medical errors and the rate of adverse events due to increases in frailty, comorbidities, and incidences of chronic conditions, falls, and dementia makes providing health care more complex and increases costs. Individuals 65 years and older are at a two-fold risk for developing adverse events when compared with individuals between the ages of 16 and 44 years. (Brennan TA, Leape LL, Laird N, et al.) Nations across the G20 will face this challenge, which necessities innovate safety interventions and new approaches in health care to design a safer health care system.


When it comes to patient safety, doing more of the same will result in: 

1- More lives will be lost 

2- More preventable harm will take place like Healthcare Associated Infections, medication errors, Anti-microbial Resistance (AMR) …etc. 

3- More money will be wasted (not to mention indirect cost and opportunity cost).

When a patient is harmed, the COUNTRY LOSES TWICE: The individual will be lost as a revenue generating source for society+ the individual will become a burden on the healthcare system because he or she will require more treatment. 

Unless we do something different about patient safety, we would risk the sustainability of healthcare systems and the overall economies. 



Establishing a G20 Patient Safety Network (Group) that will combine two types of expertise: 

1- Safety experts from healthcare and other leading industries (like Aviation, Nuclear, Oil & Gas, other)

2- Economy and Financial Experts

This will function as a platform to prioritize and come up with innovative patient safety solutions to solve Global Challenges while highlighting the return on investment (ROI) aspects.

This multidisciplinary group of experts can work with each state that adopts the addressed Global Challenge to ensure correct implementation of proposed solution.


Investment in Patient Safety – – > sustainability of healthcare systems – – > and overall economies

In conclusion, patient safety is a global priority that goes beyond healthcare. It is a challenge that requires the collective wisdom of the G20 and the overall global community.  It is not just an issue for health ministers, but it is an important issue that requires the attention of finance ministers and heads of states. The economic cost of failing patient safety could be risking the sustainability of healthcare systems and the overall global economies.


Our G20HDP Partner Harald Nusser awarded with the Schwab Foundation Price For Social Entrepreneurship

We would like to congratulate our G20 Health and Development Partnership Member, Harald Nusser, Head of Novartis Social Business for winning the Schwab Foundation Award under the category Corporate Social Intrapreneurs. Harald is awarded as one of the influential leaders within a multinational company who drive the development of new products, initiatives, services or business models that address societal and environmental challenges.

This years awards for the first time brought together the intersectoral community of social innovators at the World Economic Forum by introducing three new categories, in addition to their Social Entrepreneur awards.

For over 20 years, the Schwab Foundation for Social Entrepreneurship has recognized social entrepreneurs as a new breed of leader – values-driven, inclusive, compassionate, entrepreneurial individuals who develop sustainable new models in business, social development and environmental initiatives. They have been at the forefront of R&D for society and civilization, accelerating how we solve problems and imagining new futures through experimentation, iteration and practice.

In these two decades, they have curated and gathered over 350 leading social entrepreneurs from 70 countries in the Schwab Foundation community and embedded them into the platforms of the World Economic Forum. Together, they have demonstrated significant progress on how they approach environmental sustainability and consumption, health and education, rural development and job training, and finding new ways to advance human rights and equality in different contexts around the world.

To find out more, please click here.

New Global Ambassador joining the Partnership!

We would like to thank our new Global Ambassador, Ajay Kumar Bramdeo, Permanent Observer of the African Union to the United Nations Office in Geneva to join the G20 Health and Development Partnership. We welcome the support of the African Union and look forward to collaborating with the AU in the framework of our G20 Activities.

To find out more, please click here.

Innovative Financing Mechanisms for Healthier Nations – The G20 Health & Development Partnership Welcomes the 2019 G20 Leaders Declaration

Osaka, 28-29 June 2019

Last weekend, G20 Heads of State have assembled for this year’s G20 Summit in Osaka in order to discuss the most pressing issues that G20 nations will face in terms of the Global Economy, the Financial System, Trade and Investment to come over the next months. While the summit was dominated by topics such as the trade talks between the US and China, G20 Leaders also heavily focused on determinants for an inclusive and sustainable world that that are heavily dependent on the broader Development agenda and on Global Health.

As a first this year, Health and Finance Ministers of the G20 assembled for a dinner on 28th June in Osaka and have agreed that health is a prerequisite for sustainable and inclusive economic growth.

The G20 Health & Development Partnership, a health advocacy group that assembled over 16 cross-sectoral health organisations from across the globe and organised this year’s Health 20 Summit, welcome the ambitious G20 Leaders Declaration led by the Government of Japan that reflects the importance of the health and the wealth of nations.

Since the beginning of the first G7 Summit hosted by Japan in 1979 when the word ‘Health’ first appeared in the official statement by the Heads of State and Government, Japan has continued its leadership role by initiating The Global Fund To Fight AIDS, Tuberculosis and Malaria and the G8 Digital Opportunity Taskforce (DOT) at the Kyushu-Okinawa Summit in 2000, towards the Call for Action on Health Systems Strengthening at the G8 Hokkaido Toyako Summit in 2008.

Japan has prominently shown its leadership role in health in this year’s G20 agenda by focussing on UHC, Ageing Societies and the Management of Health Emergencies including antimicrobial resistance (AMR).

The G20 Health and Development Partnership that organised their annual Health 20 Summit in Tokyo, on 24 June, with the support of health experts from around the globe, submitted a Call to Action to G20 Heads of State and Government and Health and Finance Ministers ahead of their meeting in Osaka.

As a result of the Health 20 Summit Call to Action document and in convergence with the G20 Leaders Declaration, The G20 Health & Development Partnership welcomes the importance of sustainable financing for health and the call for greater collaboration between health and finance authorities in accordance with the G20 Shared Understanding on the Importance of UHC Financing in Developing Countries.

Attendees of the Health 20 Summit further urged the Joint Health and Finance Ministers Meeting in Osaka to become the first of a regular and meaningful joint dialogue within the annual G20 calendar with the next joint meeting held in the Kingdom of Saudi Arabia in 2020.

The H20 Summit agrees with G20 Leaders on the recognition of international public and private finance for development as well as other innovative financing mechanisms, including blended finance that can play an important role in up-scaling our collective efforts.

Participants of the H20 Summit also agreed that in order to achieve these goals emerging economies and Middle-Income Countries (MICs) need to play a more significant role in co-founding health innovation.

As there are many public and private organisations, including multilateral organisations participating in the G20, including the OECD, that act as the strategic advisor to the G20, as well as the WHO and the World Bank, are conducting work related to innovative forms of financing for health. Attendees of the Health 20 Summit believe that this work lacks high level political support and most importantly coordination. This is why Health 20 Summit participants called for the launch of a time-limited, high-level examination of innovative and blended finance initiatives that are scalable, to supplement current investments in health innovation, with the involvement of international organisations, philanthropic partners and non-traditional actors to report during the 2020 G20 Presidency of the Kingdom of Saudi Arabia and the 2020 G7 Presidency of the United States.

The Health 20 Summit also supports and welcomes the call by G20 Leaders for further action to promote stewardship of and access to antimicrobials by noting the ongoing work done by Global AMR R&D Hub, to promote R&D to tackle AMR.

Congratulating the stewardship on the digital agenda, the Health 20 Summit Call to Action expresses the support for the inclusion of the promotion of global digital health in the G20 and urge for the building of a “data free-flow with trust” at the leader’s Osaka June communiqué and Health Ministers Declaration in Okayama in October 2019 and the prioritisation of digital health in the G20 Presidency of the Kingdom of Saudi Arabia in 2020.

The G20 Health & Development Partnership (G20 HDP) is an advocacy organisation that aims to ensure that G20 countries are coordinating their health innovation strategy to tackle the growing burden of communicable and non-communicable diseases globally to promote the delivery of SDG 3. The Partnership emerged as an informal coalition of like-minded organisations during the G20 Presidency in Germany in 2017 respecting the objectives of SDG 17. Following broad interest to build on the initiative leading up to the Argentinian G20 Presidency in 2018, Sovereign Sustainability and Development (SSD) was created in late 2017 to act as the secretariat of the Partnership. During a working session in the UK Houses of Parliament in December 2017, with the support of the founding organisations, the G20 HDP was formally launched. The Partnership comprises of 16 cross-sectoral partners including product development partnerships, non-for-profit and international organisations, public-private partnerships, pharmaceuticals, associations, research institutes and academia.

Annual Health20 Summit 2019 – Financing for Global Health Innovation & Sustainable Development

Tokyo, 24th June 2019

Photo credit: Shuhei Inoue

On 24th June 2019, the G20 Partnership held their annual Health20 Summit in Tokyo, leading up to the G20 Summit and the Joint Session of Health and Finance Ministers on 28th June 2019. In the summit, the G20’s top health and health financing experts urged G20 government Leaders, Health and Finance Ministers to significantly boost investment in the health of their citizens in order to promote sustainable economic development and inclusive growth.

Meeting in Tokyo on the eve of the Osaka G20 summit, the Health 20 Summit recognised that specific innovations in health are urgently required to help achieve Universal Health Coverage by 2030.  Health experts called for Innovative Financing initiatives (IFI) to be expanded and scaled up in order to help finance the research and development needed for the new diagnostics, vaccines and medicines required to tackle the growing problem of drug resistant diseases. Moreover, attendees called for a closer cooperation between health and finance authorities in the G20 to tackle some of the most pressing challenges faced by infectious and non-communicable diseases. The Health 20 Summit also urged the G20 Heads of State and Government to recognise the inter-dependency of the emerging global digital health ecosystem where a radical new multi-stakeholder approach is required by all governments in delivering their National Digital Health Strategies.


The summit was opened by H.E. Norikazu Suzuki, Parliamentary Vice-Minister for the Ministry of Foreign Affairs of Japan congratulating the cooperation of cross-sectoral health stakeholders. H.E. Ambassador Laurent Pic, Ambassador of France in Tokyo as well as Mr Kiya Masahiko, Deputy Assistant Minister of the International Cooperation Bureau at the Ministry of Foreign Affairs urged the importance of financing of health innovation and the achievement of SGD3 Goals.

Alan Donnelly, Chair of the H20Summit and Convenor of the G20 Health & Development Partnership said: “Several G20 countries are already using innovative financing initiatives to fund this essential research, and it is for the G20 Heads of Government and Finance Ministers to agree to rapidly scale up and expand these new methods to help meet the funding deficit.”Participants of the summit formulated a Call to Action  that was jointly sent to G20 Governments ahead of the Osaka G20 Leaders’ Summit. The “Call to Action” was submitted to all G20 Heads of States, and Finance and Health Ministers prior to the G20 Summit and the Joint Session of Health and Finance Ministers on 28th June 2019.

The Health20 Summit is an annual platform, organised by The G20 Health and Development Partnership, that offers experts from across the health sectors to come together and discuss solutions for the most recent and future challenges that will halt the timely achievement of SDG3 by 2030. This year’s summit  brought together over 100 participants under the umbrella of SDG 17, to create more Partnership’s, that included senior representatives from the Japanese government, G20 Embassies in Tokyo, Product Development Partnerships, Public-Private Partnerships, NGOs, senior politicians from G20 countries, the private sector, pharmaceutical and academic institutions to explore new and innovative ways of funding research and development (R&D) and delivery in tackling the growing disease burden.

Media Coverage:

AMR represents a growing threat to public health and economic growth

(A guest comment by Dr. Elmar Nimmesgern, Secretariat Lead Global AMR R&D Hub, 27th May 2019)

Antibiotics have been a critical tool since the discovery of penicillin in 1928, saving the lives of millions of people and animals around the world. The emergence and spread of antimicrobial resistance (AMR) are reducing the efficacy of these lifesaving medicines. AMR represents a growing threat to public health and economic growth.

The Global Antimicrobial Resistance Research and Development (R&D) Hub was launched in May 2018, following a call from G20 Leaders, to address challenges and improve coordination and collaboration in global AMR R&D using a One Health approach.

It is a global partnership consisting of 15 countries, the European Commission and two philanthropic foundations steering the work through a Board of Members. The work of the Board is supported by a small Secretariat based in Berlin.

Though it arose from the G20, the Global AMR R&D Hub is open to non-G20 countries as well as non-governmental donor organisations investing in AMR R&D. Any country or organisation sharing the vision and objectives of the Global AMR R&D Hub is invited to join and strengthen the global AMR R&D landscape. The vision of the Global AMR R&D Hub is to promote high-level coordination and alignment of existing public and private funding and activities and to leverage much needed further monetary and other investments for AMR R&D initiatives.

The main objectives of the Global AMR R&D Hub are to identify and prioritise AMR R&D gaps, promote increased investments into push and pull incentives to help fill product pipelines, and to foster international research collaboration.

One of the key activities for the Global AMR R&D Hub is the development of a close to real-time dynamic dashboard to be launched in December 2019. It will become the global knowledge centre on current initiatives and publicly and privately funded AMR R&D across the One Health continuum. The dashboard will eventually lead to more efficient use of international resources through the identification of gaps, overlaps and opportunities for cross-sectoral collaboration and leveraging of resources for AMR R&D.

Consultation with relevant stakeholders is vital to the success of the work of the Global AMR R&D Hub and a Stakeholder Group has been established. The Board of Members will also receive advice from thematic Expert Advisory Groups and a group to evaluate the market potential of interventions targeting the pathogens on the WHO priority pathogen list as well as tuberculosis has been established. It is expected that this analysis will be helpful to guide the discussion around investments into push and pull incentives for AMR R&D.

The first workshop organised by the Global R&D Hub takes place in Geneva on 28 May bringing together around 100 high-level experts to discuss opportunities for investments and new and innovative financing mechanisms for AMR R&D and to give recommendations especially on how the Global AMR R&D Hub can support these activities in a One Health approach.

At 72nd World Health Assembly week, Alan Donnelly calls for enhanced collaboration with micro-entrepreneurs and between Health and Finance Ministers to advance on the issue of digital health

(Health Policy Watch, 22nd May 2019)

During this year’s World Health Assembly week in Geneva, Alan Donnelly, Convener of the G20 Health & Development Partnership (G20 HDP), highlighted the growing importance of digital health.  He advocates for collaboration between Finance and Health Ministries to scale up digital health innovations. Alan Donnelly also stressed the necessity for global health institutions and organisations, such as the UN and the WHO, to engage more extensively with the private sector. Indeed, micro-entrepreneurs and micro-businesses invent ingenious grassroot innovations that could address some global health challenges, such as achieving Universal Health Coverage by 2030. Some of these digital innovations that are featured in our Healthy Nations – Sustainable Economies report will be presented to G20 Health and Finance representatives during the G20 HDP’s Health 20 Conference in Tokyo, on 24 June; leading up to the official G20 joint Session between Finance and Health Ministers on 28th June. 

Read the full interview here:

Alan Donnelly, Convener of the G20 Partnership, calls on G20 Health and Finance Ministers for increased cooperation and scaling up innovative financing models to effectively tackle global health challenges

(Japan Times, 5th April)

In his recent interview with the Japan Times, Alan Donnelly, Convenor of the G20 Health & Development Partnership, stressed the necessity of increased multi-sectoral cooperation to effectively tackle global health challenges and highlighted the strong link between global health and the economy. Alan said that there are successful programmes now in place that the G20 leaders could tap to raise funds towards new financing efforts to not only guard against a potential pandemic, but also support other global health initiatives. Some of those financial instruments such as new bonds, like a previously created vaccine bond, could be issued. Moreover, certain kinds of new levies similar to the one in France that supports Unitaid could be created. Together with the support of Partners of the G20 Health and Development Partnership, in a recently published report “Healthy Nations Sustainable Economies,” Alan pledged that G20  Finance and Health Ministers could ask the OECD and the World Bank, together with the WHO, to create a high-level panel that would look into ways to scale up blended finance models and establishing new long-term ways of funding innovation in health. The panel’s proposals can be presented during the G20 presidency of Saudi Arabia in 2020,” he added.

Read the full interview here: